Production (Stage)
Acumen Pharmaceuticals, Inc.
ABOS
$1.02
-$0.01-0.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 102.96% | 122.67% | 90.70% | 113.87% | 42.88% |
| Gross Profit | -102.96% | -122.67% | -90.70% | -113.87% | -42.88% |
| SG&A Expenses | -4.15% | -3.18% | 3.25% | 11.58% | 20.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 70.87% | 114.20% | 101.17% | 80.89% | 35.32% |
| Operating Income | -70.87% | -114.20% | -101.17% | -80.89% | -35.32% |
| Income Before Tax | -93.61% | -125.22% | -129.72% | -76.89% | -31.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -93.61% | -125.22% | -129.72% | -76.89% | -31.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -93.61% | -125.22% | -129.72% | -76.89% | -31.54% |
| EBIT | -70.87% | -114.20% | -101.17% | -80.89% | -35.32% |
| EBITDA | -70.94% | -114.34% | -101.23% | -80.97% | -35.34% |
| EPS Basic | -91.31% | -117.44% | -107.37% | -20.78% | 9.76% |
| Normalized Basic EPS | -91.38% | -117.50% | -107.37% | -20.75% | 9.81% |
| EPS Diluted | -91.31% | -117.44% | -107.37% | -20.78% | 9.76% |
| Normalized Diluted EPS | -91.38% | -117.50% | -107.37% | -20.75% | 9.81% |
| Average Basic Shares Outstanding | 1.19% | 3.56% | 10.79% | 46.45% | 45.79% |
| Average Diluted Shares Outstanding | 1.19% | 3.56% | 10.79% | 46.45% | 45.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |